Codexis, Bristol-Myers Squibb Sign Research Agreement
Codexis, Inc. announced it has signed a research agreement with Bristol-Myers Squibb Company on pharmaceutical process research. In addition to its relationship with Bristol-Myers Squibb, Codexis has 10 strategic alliances in life science and chemistry process development, where its technology is being applied to reduce process development time and manufacturing costs while creating new intellectual property opportunities.
The research with Bristol-Myers Squibb focuses on improving biocatalyst productivity for an undisclosed product candidate in Bristol-Myers Squibb's pipeline using Codexis' proprietary pharmaceutical process re-engineering platform. Codexis will receive research funding and a milestone payment upon successful completion of certain objectives of the research. If Bristol-Myers Squibb is satisfied with the progress of the research, the agreement may subsequently be expanded to fund additional research. Financial terms were not disclosed.
Other news from the department business & finance
